BioNotebook: 3 IPOs launch, 2 file; AMAG 4Q earnings; Repros FDA update
This article was originally published in Scrip
Executive Summary
On their first day as public companies, Egalet broke even, Eleven Biotherapeutics gained 8.5% and Revance Therapeutics closed 67.8% above its initial public offering price on 6 February.
You may also be interested in...
Does Deal With Roche Signal Eleven's Doomed Fate?
Eleven Biotherapeutics Inc. more than doubled in value in early trading on June 13 before closing up 27.8% at $2.39 per share after the company said it licensed EBI-031, its lead development program, to Roche – a move that could signal Eleven's intention to wind down the eye disease-focused company.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.